Plasma high density lipoprotein small subclass is reduced in Alzheimer’s disease patients and correlates with cognitive performance

Manuscript Number: 

20-0291R1

Author(s): 
David Ames, Ashley I. Bush, Pratishtha Chatterjee, Veer Gupta, Eugene Hone, Ian James, Simon M. Laws, Ian Martins, Ralph N. Martins, Colin L. Masters, Steve Pedrini, Manfred R. Raida, Stephanie R. Rainey-Smith, Christopher C. Rowe, Hamid R. Sohrabi, Kevin Taddei, Elham Teimouri, Giuseppe Verdile, Victor L. Villemagne, Markus R. Wenk

Disclosures

David Ames

  • Nothing to Disclose

Ashley I. Bush

  • Consulting Fees:
    Collaborative Medicinal Development Pty Ltd, consulting fees
    Equity:
    Alterity Ltd, Cogstate Ltd, Mesoblast Ltd, profit share from Collaborative Medicinal Development Pty Ltd

Pratishtha Chatterjee

  • Nothing to Disclose

Veer Gupta

  • Nothing to Disclose

Eugene Hone

  • Nothing to Disclose

Ian James

  • Nothing to Disclose

Simon M. Laws

  • Consulting Fees:
    Scientific Advisory Panel Cytox Ltd

Ian Martins

  • Nothing to Disclose

Ralph N. Martins

  • Nothing to Disclose

Colin L. Masters

  • Nothing to Disclose

Steve Pedrini

  • Nothing to Disclose

Manfred R. Raida

  • Nothing to Disclose

Stephanie R. Rainey-Smith

  • Nothing to Disclose

Christopher C. Rowe

  • Consulting Fees:
    Cerveau Technology sitting fees for advisory board
    Lecture Fees:
    Biogen AAIC Seminar speaker fee

Hamid R. Sohrabi

  • Patents/Royalties
    Previously received remuneration from Takeda and Pfizer.

Kevin Taddei

  • Nothing to Disclose

Elham Teimouri

  • Nothing to Disclose

Giuseppe Verdile

  • Nothing to Disclose

Victor L. Villemagne

  • Nothing to Disclose

Markus R. Wenk

  • Nothing to Disclose